A Phase 3 interventional study of rMenB+OMV NZ in Meningococcal Disease, sponsored by Novartis Vaccines. Completed at 19 sites in 2 countries. Open to participants aged 23 Months to 27 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-04-10.
Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing 4CMenB vaccine in Meningococcal Infections — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningococcal Infections.
Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, this one is the 11th largest by enrollment, is one of 2 that started in 2010, is one of 7 in phase 3, and was the 8th registered.
243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.
Browse Meningococcal Infections studies →1 of the 21 studies testing 4CMenB vaccine in Meningococcal Infections is open now, in 1 country. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →
Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 23 Months to 27 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 9 · Phase 4 4
First in 2006; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 508 is above the median of 456 across 214 interventional studies indexed under Meningococcal Infections.
Median enrollment 508 across the 21 interventional studies. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 21 have an industry lead sponsor. The 7 most frequent:
This study is registered under Novartis Vaccines, one of the names counted as Novartis. Under that name alone:
Novartis Vaccines is the lead sponsor of 165 studies on the registry; none are open to participants now.
60 studies in Meningococcal Infections by Novartis: none open now, none under way, none of them phase 3. Of 59 finished, 48 (81%) have results posted.
Among the 60 studies in Meningococcal Infections by Novartis, this one is the 26th largest by enrollment of the 57 interventional ones that give a count, is one of 8 that started in 2010, is one of 27 in phase 3, and was the 35th registered.
Novartis’s Meningococcal Infections studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 60 in Meningococcal Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
One year antibody persistence after the fourth dose boost or two catch-up doses administered starting from 12 months of age and to evaluate the response to a a third dose boost or two catch-up dose starting at 24 months of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects assessed one year post administration of rMenB+OMV NZ and MMRV at 12th month after primary vaccination at 2nd ,4th and 6th months of age.
Biological: rMenB+OMV NZ
Subjects assessed one year post administration of rMenB+OMV NZ at 12th month and MMRV at 13th month after primary vaccination at 2nd ,4th and 6th months of age.
Biological: rMenB+OMV NZ
Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at 13th and 15th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 27 months of age.
Biological: rMenB+OMV NZ
Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at either 12th and 14th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 26 months of age.
Biological: rMenB+OMV NZ
Subjects assessed at 1 month and 6 months post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.
Biological: rMenB+OMV NZ
Subject was randomized in group B13_15_27 but treated as group B12_M13.
Biological: rMenB+OMV NZ
Drug page: 4CMenB vaccine
Subjects will be assigned to a study group based on the group assignment in the parent study (follow-on subjects). In addition, one group of naïve age-matched subjects will be recruited at the same study sites. Subjects who had received 4 doses of rMenB+OMV NZ will have one visit including one blood draw. Subjects who had received two catch-up doses in V72P13E1 will receive a third dose boost and will have 3 blood samples drawn. Naïve subjects will receive two catch-up doses and have 3 blood samples drawn.
Geometric Mean Titers (GMTs) to Assess Antibody Persistence at 12 Months After a Booster Dose of rMenB+OMV NZ Vaccination.
To assess the immunogenicity in terms of human Serum Bactericidal Assay (hSBA) GMTs through antibody persistence at 12 months after a booster (fourth) dose of Novartis Meningococcal B Recombinant Vaccine (rMenB+OMV NZ) in groups that received a three-dose primary series at 2, 4,6 months of age. Group B246_12M12 received Measles, Mumps, Rubella, Varicella (MMRV) at 12 months of age (concomitantly) and group B246_12M13 received MMRV at 13 months of age (separately). Analysis was done on Modified Intention-To-Treat (MITT) population- (Primary).
Time frame: 12 months post booster (fourth) vaccination.
Percentage of Subjects With hSBA ≥1:5 and hSBA ≥1:8 to Assess Antibody Persistence at on 12 Months After a Booster Dose of rMenB+OMV NZ Vaccination.
To assess the immunogenicity in terms of percentage of subjects with hSBA ≥1:5 and hSBA ≥1:8 through antibody persistence at 12 months after a booster (fourth) dose of rMenB+OMV NZ in groups that received a three-dose primary series at 2, 4, 6 months of age. Group B246_12M12 received MMRV at 12 months of age (concomitantly) and group B246_12M13 received MMRV at 13 months of age (separately). Analysis was done on MITT population (Primary).
Time frame: 12 months post booster (fourth) vaccination.
Geometric Mean Concentrations (GMCs) to Assess Antibody Persistence at One Year After a Booster Dose of rMenB+OMV NZ Vaccination.
To assess the immunogenicity in terms of GMCs determined by Enzyme Linked Immunosorbent Assay (ELISA) through antibody persistence at one year after a booster (fourth) dose of rMenB+OMV NZ in groups that received a three-dose primary series at 2, 4, 6 months of age. Group B246_12M12 received MMRV at 12 months of age (concomitantly) and group B246_12M13 received MMRV at 13 months of age (separately) against vaccine antigen 287-953. Analysis was done on MITT population (Primary).
Time frame: 12 months post booster (fourth) vaccination.
GMTs to Assess Antibody Persistence at 12 Months After Two Catch-up Doses and 6 Months After Booster Dose of rMenB+OMV NZ Vaccination.
To assess the immunogenicity in terms of hSBA GMTs at 12 months after two catch up doses previously administered to children at either 12 and 14 or 13 and 15 months of age and 6 months after a booster dose of rMenB+OMV NZ administered at 26 or 27 months of age. Both the groups received MMRV at 12 months of age.
Time frame: 12 months post two catch-up dose vaccination and 6 months post booster dose.
Percentage of Subjects With hSBA ≥1:5 and hSBA ≥1:8 to Assess Antibody Persistence at 12 Months After Two Catch up Doses and 6 Months After a Booster Doses of rMenB+OMV NZ Vaccination.
To assess the immunogenicity in terms of percentage of subjects with hSBA ≥1:5 and hSBA ≥1:8 at 12 months after two catch up doses previously administered to children at either 12 and 14 or 13 and 15 months of age and 6 months after a booster dose of rMenB+OMV NZ administered at 26 or 27 months of age. Both the groups received MMRV at 12 months of age.
Time frame: 6month post booster dose and 12 months post two catch-up dose vaccination.
Percentage of Subjects With at Least Four Fold Increase in hSBA Titers to Evaluate Antibody Response 1 Month Post Booster Dose of rMenB+OMV NZ Vaccination.
To assess the immunogenicity in terms of percentage of subjects with at least four fold increase in hSBA titers 1 month post booster dose of rMenB+OMV NZ administered at 26 or 27 months of age, in children previously administered two catch-up doses of rMenB+OMV NZ at either 12 and 14 or 13 and 15 months of age.Both the groups received MMRV at 12 months of age.
Time frame: 1 month post booster dose versus prebooster.
GMCs to Assess Antibody Persistence at One Year After Two Catch-up Doses and 6 Months After Booster of rMenB+OMV NZ Vaccination Against 287-953 Strain.
To assess the immunogenicity in terms of GMCs determined by ELISA at 12 months after two catch up doses previously administered to children at either 12 and 14 or 13 and 15 months of age and 6 months after a booster dose of rMenB+OMV NZ administered at 26 or 27 months of age. Both the groups received MMRV at 12 months of age.
Time frame: 12 months post two catch-up dose vaccination and 6 months post booster dose.
GMTs to Characterize Antibody Response at 1 Month and 6 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.
To assess the immunogenicity in terms of GMTs through antibody response at 1 month and 6 month post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.
Time frame: 1 month and 6 months post two catch-up doses.
Percentage of Subjects With hSBA ≥1:5 and hSBA ≥1:8 to Assess Antibody Response at 1 Month and 6 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.
To assess the immunogenicity in terms of percentage of subjects with hSBA ≥1:5 and hSBA ≥1:8 through antibody response at at 1 month and 6 month post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.
Time frame: 1 month and 6 months post two catch-up doses.
Percentage of Subjects With Four Fold Increase in hSBA to Assess Antibody Response at 1 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.
To assess the immunogenicity in terms of percentage of subjects with fourfold increases in hSBA titers at 1 month post two catch-up doses of rMenB+OMV NZ in children previously administered to naive children at 24 and 26 months of age against 4 strains. Analysis was done on MITT population (Secondary).
Time frame: 1 month post two catch-up doses versus prevaccination
GMCs to Assess Antibody Response at 1 Month and 6 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age Against 287-953 Strain.
To assess the immunogenicity in terms of GMCs to assess through antibody response at 1 month and 6 month post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age against 287-953 strain. Analysis was done on MITT population (Secondary).
Time frame: 1 month and 6 months post two catch-up doses.
Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Receiving a Booster (Third) Dose of rMenB+OMV NZ Administered at One Year After Two Catch-up Doses of rMenB+OMV NZ, Previously Administered to Children.
To assess the safety and tolerability by reporting solicited local and systemic AEs of a booster (third) dose of rMenB+OMV NZ administered at one year after two catch-up doses of rMenB+OMV NZ, previously administered to children at either 12 and 14 or 13 and 15 months of age in study V72P13E1.
Time frame: Up to 7 days after any vaccination.
Number of Subjects Reporting Unsolicited Adverse Events After Receiving a Booster (3rd) Dose of rMenB+OMV NZ Administered at One Year After Two Catch-up Doses of rMenB+OMV NZ, Previously Administered to Children.
To assess the safety and tolerability in terms of number of subjects reporting unsolicited adverse events in yerms of serious adverse events (SAEs), atleast possibly related SAEs and AEs leading to withdrawl of a booster (third) dose of rMenB+OMV NZ administered at one year after two catch-up doses of rMenB+OMV NZ, previously administered to children at either 12 and 14 or 13 and 15 months of age in study V72P13E1.
Time frame: Up to 7 days after any vaccination.
Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.
To assess the safety and tolerability by reporting solicited local and systemic adverse events of two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.
Time frame: Up to 7 days after any vaccination.
Number of Subjects Reporting Unsolicited Adverse Events After Receiving Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.
To assess the safety and tolerability in terms of number of subjects reporting unsolicited adverse events after receiving two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age. The analysis was done on safety subset.
Time frame: Up to 7 days after any vaccination
Participants were enrolled from Finland and Czech Republic study center.
| Milestone | B246_12M12 | B246_12M13 | B13_15_27 | B12_14_26 | B_24_26 | B12M13 |
|---|---|---|---|---|---|---|
| Started | 152 | 153 | 67 | 19 | 116 | 1 |
| Completed | 151 | 153 | 67 | 18 | 107 | 1 |
| Not completed | 1 | 0 | 0 | 1 | 9 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 4 | 0 |
To assess the immunogenicity in terms of human Serum Bactericidal Assay (hSBA) GMTs through antibody persistence at 12 months after a booster (fourth) dose of Novartis Meningococcal B Recombinant Vaccine (rMenB+OMV NZ) in groups that received a three-dose primary series at 2, 4,6 months of age. Group B246_12M12 received Measles, Mumps, Rubella, Varicella (MMRV) at 12 months of age (concomitantly) and group B246_12M13 received MMRV at 13 months of age (separately). Analysis was done on Modified Intention-To-Treat (MITT) population- (Primary).
| Titers | B246_12M12 | B246_12M13 | B246_12Tot |
|---|---|---|---|
| H44/76-SL (N=147,152,299) | 7.38 (5.55 to 9.83) | 8.3 (6.17 to 11) | 6.5 (5.63 to 7.5) |
| 5/99 (N=147,151,298) | 68 (52 to 91) | 90 (67 to 121) | 81 (71 to 94) |
| NZ98/254 | 1.57 (1.24 to 1.99) | 1.79 (1.4 to 2.29) | 1.91 (1.7 to 2.15) |
| M10713 (N=143,148,291) | 4.37 (3.24 to 5.9) | 3.62 (2.65 to 4.94) | 3.35 (2.88 to 3.9) |
To assess the immunogenicity in terms of percentage of subjects with hSBA ≥1:5 and hSBA ≥1:8 through antibody persistence at 12 months after a booster (fourth) dose of rMenB+OMV NZ in groups that received a three-dose primary series at 2, 4, 6 months of age. Group B246_12M12 received MMRV at 12 months of age (concomitantly) and group B246_12M13 received MMRV at 13 months of age (separately). Analysis was done on MITT population (Primary).
| Percentage of subjects | B246_12M12 | B246_12M13 | B246_12Tot |
|---|---|---|---|
| H44/76-SL (hSBA ≥1:5) (N=147, 152, 299) | 60 (51 to 68) | 64 (56 to 71) | 62 (56 to 67) |
| 5/99 (hSBA ≥1:5) (N=147, 151, 298) | 96 (91 to 98) | 99 (95 to 100) | 97 (95 to 99) |
| NZ98/254 (hSBA ≥1:5) | 18 (12 to 25) | 17 (11 to 24) | 17 (13 to 22) |
| M10713 (hSBA ≥1:5) (N=143, 148, 291) | 40 (32 to 48) | 32 (25 to 41) | 36 (31 to 42) |
| H44/76-SL (hSBA ≥1:8) (N=147, 152, 299) | 44 (35 to 52) | 47 (39 to 55) | 45 (39 to 51) |
| 5/99 (hSBA ≥1:8) (N=147, 151, 298) | 96 (91 to 98) | 98 (94 to 100) | 97 (94 to 99) |
| NZ98/254 (hSBA ≥1:8) (N=147, 153, 300) | 12 (7 to 19) | 14 (9 to 21) | 13 (10 to 18) |
| M10713 (hSBA ≥1:8) (N=143, 148, 291) | 31 (23 to 39) | 24 (17 to 31) | 27 (22 to 33) |
To assess the immunogenicity in terms of GMCs determined by Enzyme Linked Immunosorbent Assay (ELISA) through antibody persistence at one year after a booster (fourth) dose of rMenB+OMV NZ in groups that received a three-dose primary series at 2, 4, 6 months of age. Group B246_12M12 received MMRV at 12 months of age (concomitantly) and group B246_12M13 received MMRV at 13 months of age (separately) against vaccine antigen 287-953. Analysis was done on MITT population (Primary).
| Concentration IU/mL | B246_12M12 | B246_12M13 | B246_12Tot |
|---|---|---|---|
| Geometric Mean Concentrations (GMCs) to Assess Antibody Persistence at One Year After a Booster Dose of rMenB+OMV NZ Vaccination. | 360 (293 to 442) | 389 (314 to 482) | 352 (317 to 391) |
To assess the immunogenicity in terms of hSBA GMTs at 12 months after two catch up doses previously administered to children at either 12 and 14 or 13 and 15 months of age and 6 months after a booster dose of rMenB+OMV NZ administered at 26 or 27 months of age. Both the groups received MMRV at 12 months of age.
| Titers | B13_15_27 | B12_14_26 | B12+B13Tot |
|---|---|---|---|
| H44/76-SL (12months) | 14 (9.01 to 23) | 8.4 (4.13 to 17) | 10 (8 to 13) |
| 5/99 (12months) (N= 67, 18, 85) | 73 (43 to 123) | 71 (32 to 154) | 65 (49 to 85) |
| NZ98/254 (12months) (N= 67, 18, 85) | 1.67 (1.09 to 2.55) | 1.2 (0.64 to 2.27) | 1.75 (1.39 to 2.2) |
| M10713 (12months) (N= 64, 18, 82) | 3.74 (2.14 to 6.54) | 3.29 (1.43 to 7.56) | 3.4 (2.5 to 4.61) |
| H44/76-SL (6months) (N= 67, 17, 84) | 68 (41 to 113) | 70 (32 to 151) | 51 (38 to 68) |
| 5/99 (6months) (N= 67, 17, 84) | 524 (332 to 827) | 525 (263 to 1047) | 518 (405 to 664) |
| NZ98/254 (6months) (N= 67, 17, 84) | 8.87 (5.23 to 15) | 16 (7.13 to 35) | 8.8 (6.63 to 12) |
| M10713 (6months) (N= 66, 16, 82) | 30 (18 to 49) | 36 (17 to 78) | 26 (20 to 33) |
To assess the immunogenicity in terms of percentage of subjects with hSBA ≥1:5 and hSBA ≥1:8 at 12 months after two catch up doses previously administered to children at either 12 and 14 or 13 and 15 months of age and 6 months after a booster dose of rMenB+OMV NZ administered at 26 or 27 months of age. Both the groups received MMRV at 12 months of age.
| Percentage of subjects | B13_15_27 | B12_14_26 | B12+B13Tot |
|---|---|---|---|
| H44/76-SL (hSBA ≥1:5) (12months) | 75 (63 to 84) | 56 (31 to 78) | 71 (60 to 80) |
| 5/99 (hSBA ≥1:5) (12months) (N= 67, 18, 85) | 97 (90 to 100) | 94 (73 to 100) | 96 (90 to 99) |
| NZ98/254 (hSBA ≥1:5) (12months) (N= 67, 18, 85) | 18 (10 to 29) | 6 (0 to 27) | 15 (8 to 25) |
| M10713 (hSBA ≥1:5) (12months) (N= 64, 18, 82) | 39 (27 to 52) | 28 (10 to 53) | 37 (26 to 48) |
| H44/76-SL (hSBA ≥1:5) (6months) (N= 67, 17, 84) | 99 (92 to 100) | 100 (80 to 100) | 99 (94 to 100) |
| 5/99 (hSBA ≥1:5) (6months) (N= 67, 18, 84) | 100 (95 to 100) | 100 (80 to 100) | 100 (96 to 100) |
| NZ98/254 (hSBA ≥1:5) (6months) (N= 67, 18, 84) | 73 (61 to 83) | 82 (57 to 96) | 75 (64 to 84) |
| M10713 (hSBA ≥1:5) (6months) (N= 66, 16, 82) | 92 (83 to 97) | 94 (70 to 100) | 93 (85 to 97) |
| H44/76-SL (hSBA ≥1:8) (12months) (N= 67, 18, 85) | 63 (50 to 74) | 56 (31 to 78) | 61 (50 to 72) |
| 5/99 (hSBA ≥1:8) (12months) (N= 67, 18, 85) | 96 (87 to 99) | 94 (73 to 100) | 95 (88 to 99) |
| NZ98/254 (hSBA ≥1:8) (12months) (N= 67, 18, 85) | 15 (7 to 26) | 6 (0 to 27) | 13 (7 to 22) |
| M10713 (hSBA ≥1:8) (12months) (N= 64, 18, 82) | 27 (16 to 39) | 22 (6 to 48) | 26 (17 to 36) |
| H44/76-SL (hSBA ≥1:8) (6months) (N=67, 17, 84) | 91 (82 to 97) | 100 (80 to 100) | 93 (85 to 97) |
| 5/99 (hSBA ≥1:8) (6months) (N= 67, 17, 84) | 100 (95 to 100) | 94 (71 to 100) | 99 (94 to 100) |
| NZ98/254 (hSBA ≥1:8) (6months) (N= 67, 17, 84) | 52 (40 to 65) | 65 (38 to 86) | 55 (44 to 66) |
| M10713 (hSBA ≥1:8) (6months) (N= 66, 16, 82) | 86 (76 to 94) | 81 (54 to 96) | 85 (76 to 92) |
To assess the immunogenicity in terms of percentage of subjects with at least four fold increase in hSBA titers 1 month post booster dose of rMenB+OMV NZ administered at 26 or 27 months of age, in children previously administered two catch-up doses of rMenB+OMV NZ at either 12 and 14 or 13 and 15 months of age.Both the groups received MMRV at 12 months of age.
| Percentage of Subjects | B13_15_27 | B12_14_26 | B12+B13Tot |
|---|---|---|---|
| H44/76-SL (N= 66, 18, 84) | 100 (95 to 100) | 100 (81 to 100) | 100 (96 to 100) |
| 5/99 (N= 67, 18, 85) | 99 (92 to 100) | 100 (81 to 100) | 99 (94 to 100) |
| NZ98/254 (N= 65, 18, 83) | 97 (89 to 100) | 94 (73 to 100) | 96 (90 to 99) |
| M10713 (N= 62, 16, 78) | 82 (70 to 91) | 88 (62 to 98) | 83 (73 to 91) |
To assess the immunogenicity in terms of GMCs determined by ELISA at 12 months after two catch up doses previously administered to children at either 12 and 14 or 13 and 15 months of age and 6 months after a booster dose of rMenB+OMV NZ administered at 26 or 27 months of age. Both the groups received MMRV at 12 months of age.
| Concentration IU/mL | B13_15_27 | B12_14_26 | B12+B13Tot |
|---|---|---|---|
| 287-953 (6months) (N=67, 17, 84) | 2314 (1596 to 3355) | 3259 (1859 to 5712) | 2597 (2104 to 3205) |
| 287-953 (12months) | 219 (149 to 322) | 246 (138 to 437) | 227 (185 to 278) |
To assess the immunogenicity in terms of GMTs through antibody response at 1 month and 6 month post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.
| Titers | B_24_26 |
|---|---|
| H44/76-SL (1months) (N= 105) | 220 (186 to 261) |
| 5/99 (1months) (N= 103) | 455 (372 to 556) |
| NZ98/254 (1months) (N=108 ) | 27 (23 to 32) |
| M10713 (1months) (N=100) | 38 (32 to 45) |
| H44/76-SL (6months) (N=104) | 22 (18 to 27) |
| 5/99 (6months) (N= 104) | 71 (57 to 89) |
| NZ98/254 (6 months) (N= 104) | 1.88 (1.57 to 2.26) |
| M10713 (6months) (N= 104) | 8.04 (6.39 to 10) |
To assess the immunogenicity in terms of percentage of subjects with hSBA ≥1:5 and hSBA ≥1:8 through antibody response at at 1 month and 6 month post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.
| Percentage of subjects | B_24_26 |
|---|---|
| H44/76-SL (hSBA ≥1:5) (1months) (N=105) | 100 (97 to 100) |
| 5/99 (hSBA ≥1:5) (1months) (N= 103) | 99 (95 to 100) |
| NZ98/254 (hSBA ≥1:5) (1months) (N= 108) | 98 (93 to 100) |
| M10713 (hSBA ≥1:5) (1months) (N= 100) | 97 (91 to 99) |
| H44/76-SL (hSBA ≥1:5) (6months) (N=104) | 93 (87 to 97) |
| 5/99 (hSBA ≥1:5) (6months) (N= 104 ) | 96 (90 to 99) |
| NZ98/254 (hSBA ≥1:5) (6months) (N= 104) | 18 (11 to 27) |
| M10713 (hSBA ≥1:5) (6months) (N= 104) | 70 (60 to 79) |
| H44/76-SL (hSBA ≥1:8) (1months) (N=105) | 100 (97 to 100) |
| 5/99 (hSBA ≥1:8) (1months) (N= 103) | 99 (95 to 100) |
| NZ98/254 (hSBA ≥1:8) (1months) (N= 108) | 96 (91 to 99) |
| M10713 (hSBA ≥1:8) (1months) (N= 100) | 95 (89 to 98) |
| H44/76-SL (hSBA ≥1:8) (6months) (N=104) | 88 (80 to 93) |
| 5/99 (hSBA ≥1:8) (6months) (N= 104) | 96 (90 to 99) |
| NZ98/254 (hSBA ≥1:8) (6months) (N= 104) | 12 (6 to 19) |
| M10713 (hSBA ≥1:8) (6months) (N= 104) | 52 (42 to 62) |
To assess the immunogenicity in terms of percentage of subjects with fourfold increases in hSBA titers at 1 month post two catch-up doses of rMenB+OMV NZ in children previously administered to naive children at 24 and 26 months of age against 4 strains. Analysis was done on MITT population (Secondary).
| Percentage of subjects | B_24_26 |
|---|---|
| H44/76-SL (N=105) | 100 (97 to 100) |
| 5/99 (N= 101) | 99 (95 to 100) |
| NZ98/254 (N=108 ) | 96 (91 to 99) |
| M10713 (N= 99) | 85 (76 to 91) |
To assess the immunogenicity in terms of GMCs to assess through antibody response at 1 month and 6 month post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age against 287-953 strain. Analysis was done on MITT population (Secondary).
| Concentration IU/mL | B_24_26 |
|---|---|
| 287-953 strain (1months) | 5448 (4630 to 6411) |
| 287-953 strain (6months) | 383 (319 to 459) |
To assess the safety and tolerability by reporting solicited local and systemic AEs of a booster (third) dose of rMenB+OMV NZ administered at one year after two catch-up doses of rMenB+OMV NZ, previously administered to children at either 12 and 14 or 13 and 15 months of age in study V72P13E1.
| Number of subjects | B13_15_27 | B12_14_26 |
|---|---|---|
| Any Local | 64 | 16 |
| Tenderness (N=67,17) | 63 | 16 |
| Erythema (N=) | 47 | 13 |
| Induration | 37 | 9 |
| Swelling | 35 | 9 |
| Any Systemic | 53 | 15 |
| Change Eat. Habits (N=67,17) | 25 | 9 |
| Sleepiness | 22 | 7 |
| Vomiting | 4 | 0 |
| Diarrhea | 4 | 1 |
| Irritability | 40 | 14 |
| Unusual Crying | 16 | 5 |
| Rash | 1 | 0 |
| Fever ( >= 38C ) | 22 | 6 |
| Temperature (>= 40 C) | 0 | 0 |
| Medical Attend. Fever | 0 | 0 |
| Antipyr. Med. Used Prev | 55 | 12 |
| Antipyr. Med. Used Trt | 47 | 11 |
To assess the safety and tolerability in terms of number of subjects reporting unsolicited adverse events in yerms of serious adverse events (SAEs), atleast possibly related SAEs and AEs leading to withdrawl of a booster (third) dose of rMenB+OMV NZ administered at one year after two catch-up doses of rMenB+OMV NZ, previously administered to children at either 12 and 14 or 13 and 15 months of age in study V72P13E1.
| Number of Subjects | B13_15_27 | B12_14_26 |
|---|---|---|
| Any AE | 45 | 10 |
| SAEs | 2 | 1 |
| At least possibly related SAEs | 0 | 0 |
| AEs leading to withdrawal | 0 | 0 |
To assess the safety and tolerability by reporting solicited local and systemic adverse events of two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.
| Number of subjects | B_24_26 |
|---|---|
| Any Local | 110 |
| Tenderness | 109 |
| Erythema | 103 |
| Induration | 75 |
| Swelling | 58 |
| Any Systemic | 98 |
| Change Eat. Habits | 53 |
| Sleepiness | 70 |
| Vomiting | 14 |
| Diarrhea | 23 |
| Irritability | 84 |
| Unusual Crying | 47 |
| Rash | 14 |
| Fever ( >= 38C) | 44 |
| Temperature (>= 40 C) | 1 |
| Medical Attend. Fever | 2 |
| Antipyr. Med. Used Prev | 33 |
| Antipyr. Med. Used Trt | 38 |
To assess the safety and tolerability in terms of number of subjects reporting unsolicited adverse events after receiving two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age. The analysis was done on safety subset.
| Number of Subjects | B_24_26 |
|---|---|
| Any AE | 96 |
| Serious AEs | 6 |
| At least possibly related SAEs | 0 |
| AEs leading to withdrawal | 1 |
Collected over Throughout the study (solicited and unsolicited from Day 1 to Day 209). Any solicited and unsolicited adverse events, unsolicited SAE, medically attended AEs, AEs leading to withdrawal from the study were collected from day 1 through day.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| B13_15_27 | — | 2/67 (3%) | 67/67 (100%) |
| B12_14_26 | — | 1/18 (5.6%) | 18/18 (100%) |
| B24_26 | — | 6/112 (5.4%) | 110/112 (98.2%) |
| Event | B13_15_27 | B12_14_26 | B24_26 |
|---|---|---|---|
| Oral HerpesInfections and infestations | 0/67 | 1/18 | 0/112 |
| BronchitisInfections and infestations | 1/67 | 0/18 | 1/112 |
| LaryngitisInfections and infestations | 1/67 | 0/18 | 0/112 |
| CholesteatomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/67 | 0/18 | 1/112 |
| Adenoidal HypertrophyNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/67 | 0/18 | 1/112 |
| EnteritisGastrointestinal disorders | 0/67 | 0/18 | 1/112 |
| Metabolism and nutrition disordersMetabolism and nutrition disorders | 0/67 | 0/18 | 1/112 |
| Otitis MediaInfections and infestations | 0/67 | 0/18 | 1/112 |
| Pneumonia Respiratory SyncytialInfections and infestations | 0/67 | 0/18 | 1/112 |
| Event | B13_15_27 | B12_14_26 | B24_26 |
|---|---|---|---|
| Injection Site PainGeneral disorders | 63/67 | 16/18 | 109/112 |
| Injection Site ErythemaGeneral disorders | 47/67 | 13/18 | 103/112 |
| IrritabilityPsychiatric disorders | 40/67 | 14/18 | 84/112 |
| SomnolenceNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 22/67 | 7/18 | 70/112 |
| Injection Site SwellingGeneral disorders | 35/67 | 9/18 | 58/112 |
| Eating DisorderPsychiatric disorders | 25/67 | 9/18 | 53/112 |
| CryingGeneral disorders | 16/67 | 5/18 | 47/112 |
| PyrexiaGeneral disorders | 22/67 | 6/18 | 46/112 |
| DiarrhoeaGastrointestinal disorders | 5/67 | 1/18 | 24/112 |
| Upper Respiratory Tract InfectionInfections and infestations | 5/67 | 1/18 | 20/112 |
| Age, Continuous(months) | B246_12M12 | B246_12M13 | B13_15_27 | B12_14_26 | B_24_26 | B12M13 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 25 ± 1.0 | 25.3 ± 0.9 | 27.3 ± 0.9 | 26.6 ± 1.2 | 24.7 ± 1.4 | 26 ± 0 | 25.4 ± 1.3 |
| Sex: Female, Male(Participants) | B246_12M12 | B246_12M13 | B13_15_27 | B12_14_26 | B_24_26 | B12M13 | Total |
|---|---|---|---|---|---|---|---|
| Female | 87 | 68 | 37 | 9 | 61 | 0 | 262 |
| Male | 65 | 85 | 30 | 10 | 55 | 1 | 246 |
| Region of Enrollment(Number of Subjects) | B246_12M12 | B246_12M13 | B13_15_27 | B12_14_26 | B_24_26 | B12M13 | Total |
|---|---|---|---|---|---|---|---|
| Czech Republic | 105 | 113 | 47 | 14 | 66 | 0 | 345 |
| Finland | 47 | 40 | 20 | 5 | 50 | 1 | 163 |
The record gives a start of Jun 2010, a primary completion of Nov 2010 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 4 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 4CMenB vaccine